Staphylococcus aureus

In an effort to provide guidance to prescribers and encourage further research on the risk of antibiotic resistance in acne treatment, JAMA Dermatology published a clinical evidence synopsis (online June 21, 2017). Brandon L. Adler, MD, et al, reviewed five clinical trials published in 1987-2002 and 2007-2008. They found evidence that the widespread use of bacteriostatic antibiotics (topical...

Articles

Staphylococcus aureus

In an effort to provide guidance to prescribers and encourage further research on the...

Envy Medical Dermalinfusion

Envy Medical's Dermalinfusion is an advanced skin-resurfacing treatment that combines...

MedEsthetics May/June 2017 A Delicate Subject

Concerns that lead patients to seek vaginal rejuvenation treatments—procedures that...

MedEsthetics May/June 2017 Legal Issues

DUE TO CORPORATE practice of medicine doctrines, in most states the owners of...

Products

Biopelle antiaging eye treatment

The Tensage Growth Factor + Stem Cell Dual Eye Care Kit from Biopelle is a...

Safer sclerotherapy injections

The ergonomic SyrEase Syringe Adaptor from Syris Scientific allows providers...

Titanium and zinc oxide sun protection.

Epionce Daily Shield Lotion Tinted SPF 50 provides all skin types—including...

Antiaging Skin Care

Induction Therapies P.R.R. Protein Rich Retinol 1.0%, 4.0% and 8.0% feature...

Blogs

Facebook Ad Leads
By Angela (Miller) Hamilton, Facebook Marketing Expert at ReachLocal With more than 1.71 billion active users on Facebook, social media advertising is an important way for medspas and medical practices to reach local consumers online. Most facilties have a company page and perhaps purchase a few...
Addressing Employee Tardiness
By Paul Edwards, CEO of CEDR HR Solutions There’s nothing more maddening than knowing your patients are due to arrive at your door at any moment, but because one or more of your employees STILL hasn’t shown up for work, you won’t be able to take the patients back right away. Despite the many...
Reviewing Antibiotic Resistance in Acne Treatment

In an effort to provide guidance to prescribers and encourage further research on the risk of antibiotic resistance in acne treatment, JAMA Dermatology published a clinical evidence synopsis (online June 21, 2017). Brandon L. Adler, MD, et al, reviewed five clinical trials published in 1987-2002 and 2007-2008. They found evidence that the widespread use of bacteriostatic antibiotics (topical erythromycin and clindamycin and oral tetracyclines) may encourage the emergence of antibiotic-resistant strains of P acnes, via point mutations.

Some of the key findings included resistant P acnes found on the skin of untreated contacts of acne patients prescribed antibiotics. In addition, the use of topical antibiotics has been associated with resistance in staphylococcus aureus.

In one retrospective cohort of more than 100,000 acne patients, subjects treated with topical and/or oral antibiotics for at least six weeks were significantly more likely to develop upper respiratory infections during one year follow-up than patients who had not received antibiotics.

To help reduce antibiotic usage in acne treatment, the American Academy of Dermatology (AAD) recommends coadministration...

Mitchel P. Goldman Named Chairman of Calecim Advisory Board

Singapore bio-tech firm CellResearch Corporation, which manufactures the Calecim Professional skincare line, has announced that San Diego-based dermatologist Mitchel P. Goldman, MD, will be chairman of the Calecim Professional Medical Advisory Board.

CellResearch Corporation is a Singapore-based biotech company that discovered an abundant source of stem cells in the umbilical cord lining in 2004. This novel discovery is patent protected in 41 territories worldwide. Apart from the Calecim Professional line, which utilizes the stem cells, the company also owns CordLabs, which licenses cord-lining stem cell banking technology to cord blood and tissue banks. CellResearchCorp is also actively formulating a cord-lining stem cell-based wound-healing drug that is currently undergoing U.S. FDA trials for use on chronic diabetic and other hard-to-heal wounds.

Dr. Goldman is currently conducting an Institutional Review Board (IRB)-approved clinical trial using Calecim Professional Multi-Action Cream. He will also help co-development Calecim technology products and applications in clinics to further global education on growth factor technology in skincare.

“This is exciting news for both Calecim and CellResearchCorp...

Benjamin Stong, MD, Joins Domestic Abuse Advisory Council

Benjamin Stong, MD, of Kalos Facial Plastic Surgery in Atlanta has been appointed to the Cosmetic and Reconstructive Support Medical Advisory Council of the National Coalition Against Domestic Violence (NCADV). The program works in collaboration with the American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS) and benefits domestic abuse survivors who would otherwise be unable to afford such reconstructive care.

The NCADV is a nationally recognized voice for zero tolerance for domestic violence. To drive this movement, the NCADV believes in taking steps to affect public policy, helping others understand the impact of domestic violence and providing programs and educational opportunities to promote awareness of domestic abuse.

As a newly elected member of the council, Dr. Stong will help promote the Cosmetic & Reconstructive Support (CRS) Program of the NCADV, which offers survivors cosmetic surgery or reconstructive surgeries to repair head, neck and facial injuries caused by an abusive partner.

“I feel privileged and honored to be chosen by the NCADV,” said Dr. Stong. “Being invited to use my experience and expertise in plastic surgery to assist survivors of domestic abuse move towards a...

Biologic Therapy Dupixent (Dupilumab) Approved For Atopic Dermatitis

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) Injection from Regeneron Pharmaceuticals, and Sanofi for the treatment of adults with moderate-to-severe atopic dermatitis (AD).


Dupixent is a human monoclonal antibody that is designed to specifically inhibit overactive signaling of two key proteins, IL-4 and IL-13, which are believed to be major drivers of the persistent underlying inflammation in AD. It comes in a pre-filled syringe and can be self-administered as a subcutaneous injection every other week after an initial loading dose and can be used... more »

AAD Commends FDA for Indoor Tanning Restrictions

The American Academy of Dermatology (AAD) applauds the U.S. Food and Drug Administration (FDA) for proposing new regulations governing indoor tanning, including an age restriction for minors under the age of 18 as well as a risk-acknowledgement form that all adults must sign before using indoor tanning devices.


According to the AAD, statistics show that millions of people tan indoors annually and the risk of developing melanoma increases by 59% for individuals exposed to UV radiation from indoor tanning—the risk increases with each use. If the FDA’s proposed rule becomes final,... more »

ASDS Honored With 14 MarCom Awards

The American Society for Dermatologic Surgery (ASDS) and American Society for Dermatologic Surgery Association (ASDSA) were recognized with 14 awards—including three Platinums—in the 2015 MarCom Awards.


The MarCom Awards competition is administered and judged by the Association of Marketing and Communication Professionals, selecting winners “whose work serves as a benchmark for the industry.” The 2015 competition received about 6,500 entries representing more than a dozen countries.


The Platinum Award—MarCom’s top honor—was presented to ASDS in three categories: Currents... more »